Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
公司代碼DARE
公司名稱Dare Bioscience Inc
上市日期Apr 10, 2014
CEOJohnson (Sabrina Martucci)
員工數量21
證券類型Ordinary Share
年結日Apr 10
公司地址3655 Nobel Dr Ste 260
城市SAN DIEGO
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編92122-1050
電話18589267655
網址https://www.darebioscience.com/
公司代碼DARE
上市日期Apr 10, 2014
CEOJohnson (Sabrina Martucci)